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Delay in closure of ductus arteriosus in postnatal life may lead to serious consequences
and complications in an extremely premature neonate secondary to hemodynamic
alterations in regional blood flow pattern in various organs. Despite the widespread
recognition amongst neonatologists to identify a hemodynamically significant patent
ductus arteriosus (hsPDA) early in the postnatal course, there is lack of consensus in
its definition and thus the threshold to initiate treatment. Echocardiographic assessment
of PDA shunt size and volume combined with neonatologists’ impression of clinical
significance is most frequently used to determine the need for treatment of PDA.
Common clinical signs of hsPDA utilized as surrogate for decreased tissue perfusion
may lag behind early echocardiographic signs. Although echocardiogram allows direct
assessment of PDA shunt and hemodynamic alterations in the heart, it is limited by
dependence on pediatric cardiologist availability, interobserver variation and isolated time
point assessment. Electrical cardiometry (EC) is a non-invasive continuous real time
measurement of cardiac output by applying changes in thoracic electrical impedance. EC
has been validated in preterm newborns by concomitant transthoracic echocardiogram
assessments and may be beneficial in studying changes in cardiac output in premature
newborns with hsPDA. Alterations in perfusion index derived from continuous pulse
oximetry monitoring has been used to study changes in cardiac performance and tissue
perfusion in infants with PDA. Near infrared spectroscopy (NIRS) has been used to
objectively and continuously assess variations in renal, mesenteric, and cerebral oxygen
saturation and thus perfusion changes due to diastolic vascular steal from hsPDA in
preterm neonates. Doppler ultrasound studies measuring resistive indices in cerebral
circulation indicate disturbance in cerebral perfusion secondary to ductal steal. With
recent trends of change in practice toward less intervention in care of preterm newborn,
treatment strategy needs to be targeted for select preterm population most vulnerable to
Patra et al. Physiologic Alterations in hsPDA
adverse hemodynamic effects of PDA. Integration of these novel ways of hemodynamic
and tissue perfusion assessment in routine clinical care may help mitigate the challenges
in defining and targeting treatment of hsPDA thereby improving outcomes in extremely
premature neonates.
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INTRODUCTION
Ductus arteriosus is an important and necessary structure for the
fetus. It allows communication between the pulmonary artery
and descending aorta during fetal life facilitating majority of
right ventricular output to bypass the pulmonary vascular bed
and enter the descending aorta supporting systemic oxygenation.
Delay in its postnatal closure as commonly encountered in
extremely premature infants born <28 weeks gestation (1)
can result in failure of circulatory adaptation leading to
hemodynamic alterations in regional blood flow pattern in
multiple organs and serious complications in both early and
late postnatal course. A recent retrospective study examining
the incidence of patent ductus arteriosus (PDA) in extremely
premature babies found highest rate of 93% in infants born at
23–24 weeks, 64% in 25–26 weeks, and 21% in 27–28 weeks of
gestation (2).
The clinical consequences depend on the degree of left-
to-right shunting through the PDA and ductal steal. The
increase in pulmonary blood flow in the setting of prematurity
can lead to pulmonary edema, pulmonary hemorrhage,
respiratory deterioration, pulmonary hypertension, left
atrial and ventricular overload and dilation followed by left
ventricular dysfunction (3, 4). Diminished gastrointestinal,
renal, and cerebral blood flow secondary to PDA has been
historically linked to increased risk of necrotizing enterocolitis,
isolated intestinal perforation; acute kidney injury and
intraventricular hemorrhage, respectively (5). The above
adverse hemodynamic effects have led to the widespread
recognition of identifying a hemodynamically significant
PDA (hsPDA), however there is lack of consensus in its
definition. Previously published trials used variable definitions
or lacked specific treatment criteria or included more mature
gestational ages and hence the optimal threshold to identify the
infants at the highest risk of the above adverse sequelae is not
well-delineated (5–7).
Persistent patency of hsPDA is indisputably associated with
increased morbidity and mortality in premature neonates.
However, there is debate whether early medical or surgical
closure of PDA improves outcomes. Hence, in the last decade,
approach to PDA has shifted from early treatment to watchful
waiting for spontaneous closure (8). A recent pilot exploratory
trial showed similar ductal persistence rates at discharge when
early PDA intervention strategy was compared to targeted
therapy in presence of persistent hsPDA at ≥7days of life.
Extremely premature neonates of gestational age ≥26 weeks
managed with routine early treatment approach in the first
week of life had higher incidence of late-onset sepsis and longer
duration to achieve full enteral feeds with no advantage of
reducing morbidities or ductal ligation incidence at discharge.
Selective waiting and targeted approach to PDA management
although reasonable in some extremely premature babies, may
lead to prolonged exposure to ductal shunt and its associated
detrimental effects particularly in gestational age <26 weeks (9).
Data from Pediatric Hospital Information System demonstrated
a temporal association between declining pharmacotherapy for
PDA and unadjusted increases in long term pulmonary and
neurological impairment among extremely low birth weight
neonates (10). Therefore, in the current era when neonates born
as early as 22 weeks are surviving, neonatologists find themselves
vacillating and wavering in their decision of management
of PDA.
Currently echocardiographic measurements of a PDA are
considered as gold standard for assessing the magnitude and
relevance of left to right shunting in premature newborns
(11). Many authors have established echocardiographic
criteria for hemodynamic significance of a PDA (11–13).
Echocardiography gives information of a single time point
and is limited by dependence on availability of a pediatric
cardiologist and interobserver variation. Also, the vulnerability
of the patient to the PDA is incompletely assessed by an
echocardiogram with regards to disturbances in organ blood
flow and adverse hemodynamic effect in other organs which
is critical in assessing need for treatment. The clinical signs
of alteration in organ perfusion such as widening pulse
pressure, decreased mean blood pressure, fluctuations in heart
rate, hypoxemia, oliguria, worsening metabolic acidosis and
increasing respiratory support lack clinical sensitivity (14)
and may lag behind the early hemodynamic effects noted on
echocardiography (15, 16). Continuous assessment and accurate
interpretation of the variations and fluctuations in physiological
parameters associated with hsPDA can aid in timely diagnosis
and management. Current biomedical sophistication and
advancement allows processing of physiologic signals in
preterm neonate caused by failed circulatory adaptation and
hemodynamic effects of PDA. In this review, we discuss the
various novel techniques that may complement or improve the
assessment of hemodynamic alterations in PDA; these methods
have been examined and validated in clinical studies which can
further our knowledge about the hemodynamic vulnerability of
a neonate with hsPDA.
Arterial Blood Pressure and the Dilemma
of Systemic Hypotension in hsPDA
Arterial blood pressure (BP) is one of the commonly used
physiologic signals for evaluating hemodynamic status associated
with any clinical condition. Invasive arterial catheter is the
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gold standard for measuring arterial BP in the initial course
of premature newborn followed by oscillometric monitoring.
There are technical concerns with inaccurate and under or over
estimation of BP with either methods in this population (17, 18)
however its low cost, uncomplicated technique and feasibility
in small sized premature newborns makes it widely used in
the neonatal intensive care unit. Normogram for mean invasive
BP based on gestational and postnatal age has been established
in neonates (19) and most commonly practiced hypotension
criteria is mean arterial pressure less than infant’s postmenstrual
age (20). Extremely premature infants are predisposed to low
mean blood pressure in immediate postnatal period due to
myocardial and autonomic immaturity which may be further
exacerbated by foramen ovale or ductal shunting. Blood pressure
changes secondary to hsPDA may initially manifest as decrease
in diastolic BP relative to systolic BP and eventually followed by
reduction in both systolic and diastolic BP (21, 22). However,
BP in sick ventilated preterm newborns does not always
correlate with central blood flow, organ perfusion and oxygen
delivery and may be associated with normal or high cardiac
output (23–25) making sole reliance on BP for assessment of
hemodynamic magnitude of PDA not useful. Also threshold for
intervention for hypotension in preterm population varies widely
amongst neonatologists (26) due to variable evidence about long
term neurodevelopmental effects with hypotension tolerance vs.
treatment (27–29). Further, as mentioned above, changes in
BP, clinical signs of hypotension and compromised systemic
perfusionmay have a later onset compared to early signs of ductal
steal on echocardiogram. Thus, amore precise and individualized
approach for early determination of hemodynamic magnitude of
PDA is required in the truly vulnerable micro preemie.
Neonatologist Performed Targeted
Echocardiography
Echocardiography is the gold standard of predicting and
diagnosing hemodynamic significance of PDA. hsPDA may go
clinically unnoticed in initial postnatal course of a preterm
neonate as clinicals signs of hsPDA lag behind echocardiographic
measurements by mean of 2 days (16). Performance of bedside-
targeted echocardiography by neonatologists (also known as
functional echocardiography fECHO) is gaining popularity
in contemporary neonatal clinical practice to assist in early
diagnosis and enhance medical decision making although its use
continues to be limited in the United States (30).
The European special interest group for Neonatologist
Performed Echocardiography (31) describes specific parameters
to objectively quantify the hemodynamic magnitude and
relevance of PDA. Transductal dimension (measured at the
narrowest site on the pulmonary end), shunt direction, ratio
of systolic to diastolic shunt flow velocity and transductal
pressure gradient are important determinants of shunt
volume. Higher transductal shunt volumes are associated
with increased pulmonary and decreased systemic perfusion.
Further comprehensive objective measurements of pulmonary
over circulation can be estimated from left ventricular output
and parameters of left sided volume (left atrium/aortic root ratio,
left pulmonary artery diastolic flow velocity) and pressure load
that possibly explains associated morbidities such as pulmonary
hemorrhage, high need for respiratory support, and later risk
of bronchopulmonary dysplasia. Large volume of interatrial
shunts may artificially lower left atrium/aortic root ratio or
left ventricular end diastolic volume and should be carefully
evaluated (32). The impact of systemic hypoperfusion secondary
to ductal steal can be assessed by the flow direction of forward,
absent or reverse in descending aorta, celiac trunk and middle
cerebral artery during diastole. Transductal diameter ≥1.5mm
in initial 31 h of life, first appearance of doppler pulsatile ductal
flow pattern, and ratio of systolic to diastolic ductal flow velocity
>1.9 in the first 48 h are the parameters with high sensitivity and
specificity for predicting patency of ductus arteriosus (32–37).
Ductal diameter and left ventricular output are frequently
used to determine need of therapeutic intervention for hsPDA
(34, 38). Repeated assessment of above parameters on fECHO
and monitoring trends can help evaluate and establish diagnosis
of hsPDA.
Various scoring systems, incorporating measurements from
fECHO have been published to standardize the assessment of
hemodynamic severity of the PDA (12, 38). These scoring
systems utilizing fECHO parameters have been seen to decrease
risk of in hospital mortality (39) and or pulmonary hemorrhage
(39, 40) or chronic lung disease (38) in preterm infants treated
for hsPDA. Additionally, use of fECHO during treatment may
help in monitoring response to medication minimizing drug
doses and adverse effects from pharmacotherapy (41, 42). Many
of these fECHO measurements are subjective to interobserver
variations (43) and the need for additional prolonged training
(44) of neonatologists have limited its use in clinical settings
despite high value in clinical decision making. Repeated
assessment of discussed parameters on fECHO and monitoring
trends rather than following absolute cut off values may be
beneficial in evaluation of hsPDA.
Electrical Cardiometry—An Adjunct to
Echocardiogram With Continuous Data
Assessment of the hemodynamic status particularly cardiac
function is crucial for understanding the hemodynamic impact
of hsPDA in preterm neonates. In neonatal practice, invasive
blood pressure is routinely and continuously monitored in initial
days of life for premature infants followed by intermittent non-
invasive oscillometric blood pressure monitoring. Assessment
of cardiac output (CO) by interpretation of indirect variables
like blood pressure can be unreliable in premature and sick
neonates (45). Other reliable invasive method of measuring
cardiac output utilizing thermodilution catheter is not clinically
feasible in extremely premature neonates and the limitations of
sporadic information from technically demanding and operator
dependent echocardiogram has been previously discussed.
Electrical Cardiometry (EC, also known as electrical
velocimetry) has been proposed as a safe, well-tolerated,
practical, non-invasive, continuous method of measurement
of cardiac output that is reproducible in neonates of various
gestational maturity, weight and body surface area (46, 47).
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EC works on the principle of electrical bioimpedance which
is calculated based on the variation in aortic blood flow using
surface adhesive electrodes placed on the neck or scapular
area and thorax (48). Forward flow during systole causes
unidirectional configuration of erythrocytes parallel to blood
flow which results in better conductivity. During diastolic filling
stage, there is abrupt cessation of this blood flow leading to
haphazard arrangement of erythrocytes which increases the
impedance and dampens the conductivity. This difference in
impedance creates a waveform which is utilized to measure
blood velocity, stroke volume and cardiac output (49, 50).
Clinical feasibility and application of EC has been studied in
animal models (51), adult humans (52), pediatric congenital
heart disease patients (53), and in more recent years in term and
preterm neonates (47, 48, 54–56).
Authors have established the validity of EC by demonstrating
that stroke volume and cardiac output measured by EC are
comparable with echocardiogram with estimated similar bias,
precision and acceptable percentage error in neonates (47, 54,
57). These studies investigated preterm infants with hsPDA
(variable definition based on ductal size and left atrium aortic
root ratio) and found that EC cardiac output measurements
were clinically interchangeable with echocardiogram findings.
Another recent study utilized EC as one of the parameters for
early prediction of hsPDA in a cohort of neonates <32 weeks
gestation. The authors found that a trend of increased left
ventricular output on EC at 6 h of life correlated with hsPDA
requiring pharmacotherapy (7).
Despite the accumulating evidence of clinically advantageous
and acceptable values between EC and echocardiogram in
hemodynamic assessment of hsPDA, it is important to note that
reference values of premature neonate cardiac function on EC
is yet under research and not clinically established (56). Also
larger percentage of error in EC measurements is a concern in
babies on invasive mechanical ventilation particularly on high
frequency ventilation which is commonly used in clinical practice
for critically sick extremely premature neonates (54, 56). Another
limitation of EC in hemodynamic assessment of hsPDA is it
fails to measure preload or intravascular volume (56) which is
important to know to prevent injudicious volume expansion in
these patients who are at high risk of intracranial hemorrhage.
The integration of EC in clinical neonatology hence is currently
limited to trending cardiac function and the hemodynamic
impact rather than making clinical decision on absolute values.
Near-Infrared Spectroscopy and Regional
Oxygenation
One of the important aspects of hemodynamic disturbance
in hsPDA is the “diastolic run-off” that leads to attenuated
blood flow to various peripheral organs (58). Oxygen delivery
to tissues depends on blood flow and oxygen content which is
reduced in these circumstances resulting in decreased regional
oxygen saturation (RSO2) in multiple organs particularly
cerebral (cRSO2), renal (rRSO2), and splanchnic beds (sRSO2)
necessitating physiological increase in fractional tissue oxygen
extraction (FTOE) to maintain tissue oxygen requirement in
premature neonates. Use of NIRS has progressed from being
a research tool to clinical bedside device for non-invasive,
continuous assessment of this changing oxygen dynamics in
presence of hsPDA (59–61) as well as other clinical applications
in neonatology.
NIRS technology uses light from infrared spectrum with
wavelength between 700 and 1,000 nm. As light passes through
the tissue, it is partly absorbed, reflected and scattered. Probes
comprising of transmitter and receiver optodes applied on skin,
detects the reflected portion of light which varies depending
on the absorptive capacity of the molecules present. NIRS
measures oxygen saturation by assessing the relative amount
of oxyhemoglobin and deoxyhemoglobin content in the tissue
(62). Due to deeper penetrance of infrared light in the tissue,
signal for NIRS is derived from all vascular beds with major
contribution from venous compartment (75%) followed by
arterial and capillary (20 and 5% (63) which makes NIRS
measurements specific and reflective of regional tissue oxygen
balance by calculating oxygen delivery and consumption (62).
Unlike pulse oximetry that calculates arterial oxygen saturation,
NIRS provides information on alteration in tissue oxygen
consumption which may be an early marker of perfusion injury
(62, 64) making it complementary to pulse oximetry.
Specialized flexible mini-sensors as well as smaller sized adult
sensors are available for use in neonates (65) that can be applied
on the skin surface on forehead, flank region and periumbilical
region to assess cRSO2, rRSO2, and sRSO2, respectively (66).
Reference values of various sensors used in neonates have been
published (67). Various authors have published reference ranges
for cRSO2 starting from birth through initial weeks of life and
advancing postnatal age for both term (68–70) and preterm
infants (71, 72). Gestational age stratified normative values for
cRSO2 in preterm neonates <32 weeks have been validated for
use in first 72 h of life (65).
NIRS monitoring can aid in early recognition of hsPDA
by identifying the magnitude of compromise in renal, cerebral
and mesenteric circulation. Studies have reported decreased
rRSO2 level of 61 ± 3% is associated with hsPDA with
further decreased level of < 43% predicting the need for
PDA closure (73, 74). Positive correlation was noted between
ductal size and persistently low cRSO2 levels in infants with
ductal patency irrespective of its hemodynamic relevance (75).
Prolonged exposure to lower cerebral oxygenation as seen in
infants with persistent patency of ductus requiring surgical
closure is associated with impaired brain growth and poor
neurodevelopmental outcomes (76, 77).
Additional utility of NIRS may be in monitoring of
tissue perfusion during and following pharmacotherapy or
surgical intervention for hsPDA. Studies have shown prompt
improvement in cerebral and mesenteric perfusion after
pharmacological and surgical closure of PDA (78, 79). Brief
improvements in end-organ perfusion may be followed by
reduction in regional blood flow in post ductal ligation
patients owing to decreased left ventricular cardiac output.
Continuous and concurrent monitoring of regional oxygenation
in brain and kidneys perioperatively may enable clinicians
to diagnose post ligation cardiac syndrome before the onset
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of clinical symptoms related to decreased left ventricular
output (80).
Perfusion Index and Alteration in
Peripheral Perfusion
There is growing controversial evidence in the neonatal literature
that arterial blood pressure may not be a reliable indicator for
estimation of peripheral perfusion in a premature neonate (81,
82). Early identification of compromised peripheral perfusion in
a premature neonate with PDA is important for clinical decision
making about its hemodynamic impact. Goal of minimizing
handling in such patient cohort makes serial echocardiogram
difficult to perform.
Peripheral pulse-oximetry is a routinely and readily applied
monitoring device for premature neonates which does not
require any special preparation or handling. Pulse oximeters
generate a photoplethysmography waveform at infrared and
red wavelengths. Perfusion index (PI) is a non-invasive
method of objectively measuring peripheral perfusion from
the plethysmography signal generated by pulse oximeters and
represents the ratio of light absorbed by pulsatile elements such
as arteries and non-pulsatile elements such as blood in venous or
capillary bed, bone, connective tissue etc. (83, 84). PI has been
shown to be an objective indicator of hemodynamic alterations
and correlate with peripheral perfusion, cardiac output, and
stroke volume (84, 85).
Studies have examined PI values in healthy and sick term
neonates (86) as well as preterm infants (87) with an aim to derive
normative values. Authors have also demonstrated PI values in
first week of life in babies with ductal dependent circulation (88).
Difference in PI measurements between right upper extremity
(pre ductal) and either of lower extremities (post ductal) may be
indicative of poor post ductal perfusion and thus suggestive of
presence of hsPDA (89). Changes in PI can also be affected by
changes in skin temperature at monitoring site (84).
Decrease in superior vena cava (SVC) flow may be a novel
marker of compromised systemic circulation in neonates with
hsPDA (90). PI has been shown to correlate with SVC flow
in premature neonates and has been associated with volume
responsiveness in sick neonates (91, 92). Even though increased
pulsatile component from bounding pulses in hsPDA can
falsely increase PI more than true perfusion, authors found the
correlation of PI with SVC flow remains valid discerning the
hemodynamic impact of the PDA in a cohort of premature
newborns born <32 weeks of gestation (91).
Other authors reported that the PI of the lower extremities
(post-ductal) is decreased compared to the right arm (pre-
ductal) in preterm infants with hsPDA which measured by
delta PI of a certain cut off value strongly correlated with the
echocardiographic diagnosis of hsPDA (93). In another study
that reviewed the relation of PI and PDA, authors noted that
delta PI, delta PI variability, and mean pre-ductal PI measured
4 h prior to echocardiography reliably detected PDA in preterm
FIGURE 1 | Monitoring of hsPDA in the NICU. fECHO, functional echocardiogram; LA, left atrium; Ao, aortic root; LPA, left pulmonary artery; ASD, atrial septal defect;
PFO, patent foramen ovale; LVO, left ventricular output; EC, electrical cardiometry; NIRS, near infrared spectroscopy; cRSO2, cerebral regional oxygen saturation;
rRSO2, renal regional oxygen saturation; sRSO2, splanchnic regional oxygen saturation.
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infants (94). PI is a simple, continuous dynamic measure of
peripheral perfusion which may be a useful adjunct in helping
identify preterm babies vulnerable to circulatory adversities of
a hsPDA.
Other Biomarkers for Early Detection
The review of physiologic alterations secondary to hsPDA would
be incomplete without discussion of certain biomarkers that have
been studied and incorporated in clinical practice for assessment
of hemodynamic significance of PDA. Cardiac peptides such
as B-type (Brain) natriuretic peptide (BNP) and N-terminal
pro-BNP(NT-proBNP) have been studied extensively for early
detection as well as monitoring therapy of hsPDA. NT-pro BNP
is a marker of heart failure that increases due to ventricular
volume and pressure overload in hsPDA. Normative values for
this peptide in plasma in first week of life has been studied
at various gestational ages, with lower normal values noted in
TABLE 1 | Advantages and limitations of methods for bedside hemodynamic











• Does not measure organ
perfusion/oxygen delivery
• Detects late sign of hsPDA
Targeted
echocardiography
• Early assessment of PDA
hemodynamics










• Continuous monitoring of
cardiac function
• Precise values comparable to
echocardiography
• Assess early signs of hsPDA
(change in LVCO)
• Evolving reference values in
preterm
• Discrepancy in neonates on
invasive high
frequency ventilation
NIRS • Continuous monitoring
• Non invasive
• Assessment of peripheral
organ perfusion
• Multiple site assessment
• Trend monitoring
• Evolving site specific
reference values in preterm







• Correlates with change in
organ blood flow
• Trend monitoring








• Correlation between serum
and urinary NT-proBNP
• Abnormal values are not
specific to PDA
hsPDA, hemodynamically significant patent ductus arteriosus; LVCO, left ventricular
cardiac output; NT-proBNP, N-terminal B-type natriuretic peptide; NIRS, near
infrared spectroscopy.
term infants compared to preterms (95). Various authors have
examined the association of plasma BNP and NT-proBNP levels
with echocardiographic parameters of hemodynamic significance
(96, 97). Serum cut off values have been investigated for early
detection of hemodynamic significance by day of life 3 (98),
predicting probability of spontaneous ductal closure (99) and
developing a scoring system for PDA and associated outcomes
(100). Further non-invasive avenues have been explored recently
with study of urinary NT-proBNP to predict ductal diameter
(101) and non-response to pharmacotherapy (102, 103). Patients
with medically treated hsPDA can have persistently elevated
urinary NT-proBNP levels and NT-proBNP/creatinine ratio on
day of life 14 indicative of cardiac strain secondary to residual
volume overload from ductal shunt beyond its pharmacological
closure (104).
Alterations of organ perfusion associated with hsPDA can lead
to production of ischemia modified albumin, serum levels of
which were found to be elevated in cohort of preterm neonates
with hsPDA (105). Relationship of end tidal carbon monoxide
measured non-invasively in exhaled gas and hsPDA has been
studied in preterm infants as carbon monoxide is a known
regulator of muscle relaxation and may be implicated in the
physiologic closure of ductus arteriosus. Higher end tidal carbon
monoxide levels early after birth was associated with hsPDA
secondary to relaxant effect of carbon monoxide on ductal
muscular tone (106).
Elevated nucleated red blood cell (NRBC) count at birth is
related to chronic uterine hypoxia which may predispose to PDA.
A recent prospective study of preterm infants, showed differences
in absolute NRBC count with ductal size and hemodynamic
significance of PDA as measured by echocardiogram. The
authors proposed cut off absolute NRBC levels to predict
hsPDA (107).
There is ambiguous data on association of thrombocytopenia
with hsPDA and its influence on response to treatment. Presence
of low platelet count and high platelet distribution width
in preterm neonates is shown to be associated with hsPDA
(108). There is report of neonates with platelet dysfunction (as
measured by platelet function analyzer-100) to have prolonged
ductal patency as detected on echocardiography in first 72–96 h
of life (109).
CONCLUSION
The definition of hsPDA and the population it applies to,
continues to develop and unfold with accumulation of further
evidence of novel ways of assessment and outcomes. This
review discusses the role of various continuous modes of
tapping and analyzing physiologic variables resulting from a
hsPDA beyond the cardiologist’s echocardiogram as summarized
in Figure 1. Such continuous monitoring allows better and
earlier understanding of the magnitude of ductal shunting by
assessing the vulnerability of organs at risk of over-circulation
or hypoperfusion. There is emerging evidence that routine
and widespread treatment for PDA in preterm infants is not
necessarily associated with improved outcomes (110). However,
Frontiers in Pediatrics | www.frontiersin.org 6 February 2021 | Volume 9 | Article 648584
Patra et al. Physiologic Alterations in hsPDA
there is a cohort of extremely premature infants of the
most immature gestation with need for precise and deliberate
approach for early identification of severe hemodynamic
disturbance associated with hsPDA in the first week of life.
Further research for risk stratification to identify this select
cohort of neonates is needed. Advantages and limitations of
various modalities for ductal hemodynamic monitoring has been
summarized in Table 1. The continuous complementary data for
monitoring of this hemodynamic disturbance is encouraging,
however prior to integration in clinical care, the question whether
assessment of these parameters and resulting interventions lead
to enhancement in short- or long-term outcomes will need to be
answered. Also, withmost of these parameters lacking established
reference values in preterm neonates, currently they are useful
at the bedside primarily for trending of physiologic alterations
specific to a patient rather than indicating treatment threshold.
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